Replies to post #207297 on Biotech Values

[DewDiligence]

PTLA—BMY and PFE appear to be betting on approval?

Different drug! BMY and PFE loaned money to PTLA for the Annexa A (FXa antidote) program, not for Betrixaban.

For BMY/PFE, Betrixban is a potential competitor to Eliquis, so they would rather see Betrixaban fail.